Assertio Holdings (ASRT) Net Income towards Common Stockholders (2019 - 2026)
Assertio Holdings' (ASRT) quarterly Net Income towards Common Stockholders came in at -$18.9 million in Q1 2026, down 39.72% year-on-year from -$31.3 million in Q1 2025, and down 58.56% quarter-over-quarter from -$11.9 million in Q4 2025.
Assertio Holdings (ASRT) Net Income towards Common Stockholders (2019 - 2026) Analysis & Trends
Assertio Holdings has disclosed Net Income towards Common Stockholders across 8 years of filings, most recently posting -$18.9 million for Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at -$18.9 million, down 39.72% year-over-year; the trailing twelve-month figure through Mar 2026 was -$35.7 million (down 16.55% YoY), and the FY2025 annual result was -$30.3 million, down 40.27% from the prior year.
- Net Income towards Common Stockholders came in at -$18.9 million for Q1 2026 at Assertio Holdings, down from -$11.9 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $88.6 million in Q4 2022 to a low of -$279.5 million in Q3 2023.
- The 5-year median for Net Income towards Common Stockholders is -$3.6 million (2024), against an average of -$17.2 million.
- Across the five-year window, Net Income towards Common Stockholders jumped 1811.83% in 2022 and slumped 6797.27% in 2023, its largest moves.
- Assertio Holdings' Net Income towards Common Stockholders stood at $88.6 million in 2022, then sank by 164.78% to -$57.4 million in 2023, then jumped by 81.62% to -$10.5 million in 2024, then declined by 12.73% to -$11.9 million in 2025, then plunged by 58.56% to -$18.9 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$18.9 million (Q1 2026), -$11.9 million (Q4 2025), and $11.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 366.00 Mn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 1.99 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 118.42 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | -92.12 Mn |
| 10 | Assertio Holdings | 150.78 Mn | 79.21 Mn | 7.22 Mn | -18.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.86 Mn |
| Dec 31, 2025 | -11.89 Mn |
| Sep 30, 2025 | 11.45 Mn |
| Jun 30, 2025 | -16.35 Mn |
| Mar 31, 2025 | -13.50 Mn |
| Dec 31, 2024 | -10.55 Mn |
| Sep 30, 2024 | -2.92 Mn |
| Jun 30, 2024 | -3.63 Mn |
| Mar 31, 2024 | -4.48 Mn |
| Dec 31, 2023 | -57.39 Mn |
| Sep 30, 2023 | -279.54 Mn |
| Jun 30, 2023 | 8.47 Mn |
| Mar 31, 2023 | -3.48 Mn |
| Dec 31, 2022 | 88.59 Mn |
| Sep 30, 2022 | 4.17 Mn |
| Jun 30, 2022 | 7.83 Mn |
| Mar 31, 2022 | 9.06 Mn |
| Dec 31, 2021 | 4.63 Mn |
| Sep 30, 2021 | 3.74 Mn |
| Jun 30, 2021 | -14.17 Mn |